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Themitotic kinesin KIF11 (also called Eg5) plays critical roles in spindle functions. Although
a number of small-molecule inhibitors of KIF11 are currently in clinical development, drug-
resistance could be developed through compensation by another kinesin called KIF15. Us-
ing a newly developed infrared-based cell system, we discovered that the effectiveness of
one of the latest generations of KIF11 inhibitor (SB743921) could be enhanced with several
inhibitors of Aurora A kinase. Evidence including live-cell imaging and isobologram anal-
ysis indicated that targeting KIF11 and Aurora A together promotedmonoastral spindle for-
mation and mitotic catastrophe synergistically, supporting a model of parallel pathways of
centrosome regulation by Aurora A and KIF11. We also developed a KIF15-dependent
SB743921-resistance cell model. Significantly, the drug-resistance could also be overcome
with Aurora A inhibitors. These results provide a molecular basis for increasing the effec-
tiveness of Aurora A and KIF11 inhibitors and tackling problems of drug resistance.
ª 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction One important class of mitotic target for anticancer drugsAntimitotic drugs are among the most important chemother-
apeutic agents available. Archetypal examples include spindle
poisons that inhibit microtubules depolymerization (e.g. tax-
anes) or polymerization (e.g. vinca alkaloids). The spindle-
assembly checkpoint is artificially activated by spindle poi-
sons, resulting in mitotic block followed by a unique form of
cell death often termed mitotic catastrophe (Chow and Poon,
2010). The major shortcoming of anti-microtubule agents is
that microtubules are also critical for other cellular functions
such as intracellular transport and neuronal function. More
specific inhibitors of mitosis would avoid the side effects of
anti-microtubule agents such as neuropathy.fax: þ852 23581552.
oon).
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ochemical Societies. Publis mitotic kinesin. KIF11 (also called Eg5, KSP, HKSP, KNSL1,
and TRIP5) is a tetrameric plus-end directed microtubule mo-
tor of the Kinesin-5 family (Lawrence et al., 2004), which local-
izes along the interpolar spindle microtubules and spindle
poles (Cochran et al., 2004). KIF11 is implicated in various
mitotic microtubule functions including microtubule cross-
linking, antiparallel microtubule sliding, and bipolar spindle
formation, thereby ensuring the fidelity of chromosome
segregation.
The expression of KIF11 is closely related to cell prolifera-
tion and cancer. Overexpression of KIF11was found in bladder
cancer (Ding et al., 2011) and pancreatic cancer (Liu et al.,
2010). Furthermore, transgenic mice overexpressing KIF11ished by Elsevier B.V. All rights reserved.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 4 0 4e1 4 1 8 1405are prone to develop a variety of tumors (Castillo et al., 2007).
These and other observations favor KIF11 as an attractive
target for chemotherapy.
The first small-molecule inhibitor of KIF11 (KIF11i), monas-
trol, was identified using a phenotypic screen designed to
identify antimitotic compounds that do not directly interfere
with microtubule dynamics (Mayer et al., 1999). Monastrol in-
duces the formation of monoastral spindle, resulting in an
activation of the spindle-assembly checkpoint followed by
apoptosis (Huszar et al., 2009). Nevertheless, the clinical po-
tential of monastrol is limited because of its relatively weak
KIF11 inhibitory activity and the variety of side effects associ-
ated with high dosages.
Newer generations of KIF11i including SB743921 have sub-
stantially higher potency and specificity towards KIF11 than
monastrol (Holen et al., 2011). Nevertheless, potential issues
that apply to many drugs in general, including tolerance and
drug-resistance, could hamper their clinical development. A
solution to these problems is to adopt combinatorial treat-
ments to target multiple mitotic regulators simultaneously.
Synergism between two drugs may allow lower doses to be
used than in single drug treatment. Another rationale of tar-
geting multiple mitotic regulators is that drug resistance
developed in cancer patients treated with single-target drugs
is often due to the activation of alternative pathways.
Herewe studied one of the latest KIF11i, SB743921, which is
an improved version of Ispinesib (SB715992) currently in
phase I/II trials (Holen et al., 2011). We identified two AURKA
inhibitors could enhance the mitotic catastrophe induced by
SB743921. Moreover, AURKA inhibitors could overcome drug-
resistance developed against SB743921. One obstacle of iden-
tify compounds that act synergistically is the cost and time
involved in screening. To tackle this, we developed an
infrared-based cell system for reporting cell proliferation.
This proof-of-principle study indicates that this cost-
effective and sensitive approach can be used for many types
of drug screening.2. Materials and methods
2.1. DNA constructs
Plasmid expressing iRFP (Filonov et al., 2011) was obtained
from Addgene (Cambridge, MA, USA). Plasmid expressing
iFP1.4 (Shu et al., 2009) was a gift from Roger Tsien (University
of California, San Diego). Histone H2B-GFP construct was a gift
from Tim Hunt (Cancer Research UK).2.2. RNA interference
Cells were transfected with siRNA (10 nM unless stated other-
wise) by Lipofectamine RNAiMAX (Life Technologies, Carls-
bad, CA, USA). Stealth siRNA targeting AURKA
(GGCCAAUGCUCAGAGAAGUACUUGA), KIF11 (GAGAGAUUCUGUG-
CUUUGGAGGAAA) and control siRNA were obtained from Life
Technologies; siRNA against KIF15 (GCGGUUAUAAUGGUACCAU)
was obtained from Genepharma (Shanghai, China).2.3. Cell culture
The HeLa used in this study was a clone that expressed the
tTA tetracycline repressor chimera (Yam et al., 2000). H1299
cells were obtained from the American Type Culture Collec-
tion (Manassas, VA, USA). Cells were propagated in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% (v/
v) calf serum (Life Technologies) (for HeLa) or fetal bovine
serum (Life Technologies) (for H1299) and 50 U/ml of penicillin
streptomycin (Life Technologies). Cells were cultured in hu-
midified incubators at 37 C in 5% CO2. Unless stated other-
wise, cells were treated with the following reagents at the
indicated final concentration: Alisertib (Selleck Chemicals,
Houston, TX, USA) (62.5 nM), Barasertib (Selleck Chemicals)
(12.5 nM), MG132 (SigmaeAldrich) (10 mM), MK-5108 (Selleck
Chemicals) (125 nM), monastrol (Enzo Life Sciences, Farming-
dale, NY, USA) (25 mM), RO3306 (Enzo Life Sciences) (2.5 mM),
SB743921 (Selleck Chemicals) (10 nM). Cells were transfected
with plasmids using a calcium phosphate precipitation
method (Ausubel et al., 1995). Trypan blue analysis (Poon
et al., 1995) and clonogenic survival assays (Marxer et al.,
2013) were performed as described previously. WST-1 assays
were performed according to the instructions of themanufac-
turer (Roche Applied Science, IN, USA). Cell-free extracts were
prepared as described previously (Poon et al., 1995).2.4. Generation of stable cell lines
HeLa and H1299 cells expressing iRFP were generated by
transfection followed by cell sorting. Cells were transfected
with an iRFP-expressing construct and the iRFP-positive cells
were enriched by sorting using a flow cytometer (FACSAria
II, Becton Dickinson, Franklin Lakes, NJ, USA) using a 633-
nm red laser for excitation. The cells were propagated for
one week before being sorted again. Three rounds of sorting
were performed. HeLa cells that stably expressed histone
H2B-GFP were described previously (Chan et al., 2008). To
generate SB743921-resistant cells, HeLa or H1299 cells were
cultured in the presence of 2.5 nM of SB743921 for 2 weeks.
The cells were then subcultured with limited dilution in
5 nM of SB743921 for three weeks. Individual colonies were
isolated and tested for resistance to 10 nM of SB743921-
induced G2/M arrest with flow cytometry. The cells were sub-
sequently propagated in the absence of SB743921.2.5. Infrared imaging
Infrared images of cells expressing iRFP or iFP1.4 were ac-
quired and quantified with a ODYSSEY CLx system (LI-COR
Biosciences, Lincoln, NE, USA). The following parameters
were used: focus offset (3.0 mm), resolution (196 mm), quality
(low), and intensity (6). Unless stated otherwise, the 700 nm
channelwas used. Background obtained from culturemedium
only was subtracted from the readings.2.6. Flow cytometry
Flow cytometry analysis after propidium iodide staining was
performed as described previously (Siu et al., 1999).
Figure 1 e Developing an infrared fluorescent cell model for drug screening. (A) Expression of infrared fluorescent proteins. HeLa cells were
transfected with a blank vector or plasmids expressing IFP1.4 or iRFP. A plasmid expressing histone H2B-GFP was co-transfected to serve as a
transfection marker. Fluorescence images were acquired with a Cy5.5 filter set for IFP1.4 and iRFP and a GFP filter set for the histone H2B-GFP.
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The setup and conditions of time-lapse microscopy of living
cells were as previously described (On et al., 2011).
2.8. Drug synergism studies
HeLa cells expressing iRFP were seeded onto 96-well plates
(1000 cells/well) at 24 h before drug treatment. The cells
were treated with different chemicals (see Fig S1 for list and
concentrations used) either on their own or together with
1 nM of SB743921. The iRFP intensity was analyzed with an
infrared imager at 96 h after drug treatment. The relative
cell proliferation after single drug treatment was normalized
to the untreated control and the relative cell proliferation after
co-treatment with SB743921 was normalized to cells treated
with SB743921 alone.
2.9. Isobologram analysis
The combination effects of two treatments were analyzed ac-
cording to the median-effect method of Chou and Talalay
(Chou and Talalay, 1984). Each dose-response curve was
used to calculate the isobologram and the linear correlation
coefficient of the median-effect plot (r). The combination in-
dex (CI) at different effective dose (ED) was calculated accord-
ing to Chou and Talalay using Calcusyn Version 2.1 (Biosoft,
Cambridge, UK). CI value <1 indicates synergistic effect
(0.1e0.5 strong synergism; <0.1 very strong synergism); CI
value of 1 indicates additive effect; and CI value >1 indicates
antagonistic effect.
2.10. mRNA expression
The conditions of RT-PCR were as previously described
(Chow et al., 2013) using primers for TPX2 (50-GATTCATGGTTT-
GAGGAGAAGG-30; 50-TTCTGCCTCTTTGTAGTAAGTG-30), actin (50-
GGGAAATCGTGCGTGACATT-30; 50-GGAACCGCTCATTGCCAAT-30),
and KIF15 (50-AGAAGGGATGAGATTGAAGGA-30; 50-CGTAGTAA-
GAAGGTAAGTTTGGAG-30).
2.11. Antibodies and immunological methods
Antibodies against AURKA (BD Biosciences, Franklin Lakes, NJ,
USA), CDC27 (BD Biosciences), cyclin B1 (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), KIF11 (BD Biosciences),(B) Detection of iRFP using an infrared imager. HeLa cells were transfected
infrared imaging system using either 700 nm or 800 nm. Both IFP1.4- and iR
(C) Detection of iRFP-expressing cells using colony formation assays. HeLa
on a 6-well plate. The plate was scanned with an infrared imager on the indi
violet. (D) iRFP provides a broad linear range for measuring cell proliferat
expressing cells were seeded onto a 96-well plate in triplicates. At 6 h after
and quantified (upper panel). The cells were then processed for WST-1 cel
(E) Infrared signal is directly proportional to the cell number. HeLa cells e
indicated time points, the plates were first scanned with an infrared imager
Mean ± SD of triplicate samples. (F) Growth curves as quantified by infrare
seeded onto a 96-well plate in triplicates. The wells were scanned with an in
Mean ± SD of triplicate samples.phospho-histone H3Ser10 (Santa Cruz Biotechnology), KIF15
(Santa Cruz Biotechnology), PARP1 (BD Biosciences), cleaved
PARP1(Asp214) (BD Biosciences), TPX2 (Biolegend, San Diego,
CA, USA), Alexa Fluor 488 conjugated a-tubulin (Life Technol-
ogies), and g-tubulin (Santa Cruz Biotechnology) were ob-
tained from the indicated suppliers. Immunoblotting was
performed as described (Poon et al., 1995).
2.12. Fluorescence microscopy
Cells grown on poly-L-lysine-treated coverslips were fixed
with ice-cold methanol at 20 C for 10 min. The cells
were then washed three times with phosphate buffered sa-
line (PBS) for 5 min each, blocked and permeabilized with
3% bovine serum albumin (BSA) and 0.2% Triton X-100 in
PBS at 25 C for 30 min. The subsequent incubation steps
were followed by three times washing with wash buffer
(1% BSA and 0.2% Triton X-100 in PBS) for 5 min each time.
The cells were first incubated with anti-g tubulin antibodies
in wash buffer and followed by Alexa Fluor 594 goat anti-
mouse IgG secondary antibody (Life Technologies) in wash
buffer for 2 h at 25 C. The cells were further incubated
with Alexa Fluor 488 conjugated a-tubulin antibodies in
wash buffer. DNA was stained with Hoechst 33258 (0.5 mg/
ml in wash buffer) for 5 min. After being washed three times
with wash buffer, the coverslips were mounted with 2%(w/v)
N-propyl-gallate (SigmaeAldrich) in glycerol. The fluores-
cence images were acquired with a Nikon TE2000E
microscope.3. Results
3.1. Developing an infrared fluorescent cell model for
drug identification
Wesought to establish an improved cellular systemto facilitate
drug discovery. Desirable features include the ability to report
proliferation with high sensitivity, a broad linear range,
providing temporal information, as well as being rapid and
economical to perform. An infrared-based system meets the
above criteria. Recent advances in infraredfluorescent proteins
produce probes, such as IFP1.4 (Shu et al., 2009) and iRFP
(Filonov et al., 2011), which are bright and well tolerated by
mammalian cells. Transient expression in HeLa cells indicated
that iRFP was significantly brighter than IFP1.4 (Figure 1A). Asas in panel (A). When near confluence, the plates were imaged with an
FP-expressing cells could be detected using the 700 nm channel only.
cells stably expressing iRFP were generated and plated at low density
cated days. On day 12, the cells were also fixed and stained with crystal
ion. Two-fold serial dilutions (from 27,200 to 27 cells) of iRFP-
seeding, the plate was scanned using an infrared imaging system (left)
l proliferation assay (bottom panel). Mean ± SD of triplicate samples.
xpressing iRFP were seeded onto 60-mm plates in triplicates. At the
before harvested for trypan blue cell counting with a haemocytometer.
d imaging. The indicated number of HeLa cells expressing iRFP were
frared imager at different time points and the iRFP signals quantified.
Figure 2 e Identification of chemicals that act synergistically with KIF11i. (A) Growth inhibition by SB743921. HeLa cells expressing iRFP were
seeded onto 96-well plates and incubated with buffer or different concentrations of SB743921 (in triplicates). During the next five days, the plate
was scanned with an infrared imaging system (upper panel) to quantify the infrared signals (lower panel). Mean ± SD of triplicate samples. (B)
ED50 of SB743921 on HeLa cells. Cells expressing iRFP were treated with SB743921 as described in panel (A). At 96 h after treatment, the iRFP
intensity was quantified using an infrared imager (upper panel). The cells were then harvested and analyzed with WST-1 assay (lower panel).
Mean ± SD of triplicates. The ED50 values obtained from the two methods are shown. (C) Chemicals that act synergistically with SB743921. HeLa
cells expressing iRFP were seeded onto 96-well plates (1000/wells) at 24 h before the experiment. The cells were treated with different chemicals
(see Figure S1 for the list and concentrations used) either on their own or together with 1 nM of SB743921. After incubation for 96 h, the iRFP
intensity was analyzed with an infrared imager. The relative cell proliferation after single drug treatment was normalized to the untreated control;
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(684/708) are similar to that of the IRDye 680 dye used in stan-
dard desktop infrared imaging systems, we evaluated if the
iRFP-expressing cells can be detected using infrared imaging
systems. Indeed, cells expressing iRFP could be readily detected
using an ODYSSEY infrared imaging system (Figure 1B).
To generate cells stably expressing iRFP, HeLa cells were
transfected with an iRFP-expressing plasmid and selected by
sorting with flow cytometry. The mixed population contained
predominantly iRFP-positive cells (Figure 1C). Detection of
infraredwas very sensitive because colonies could be detected
using an infrared imager as early as 4 days after plating (be-
tween 32 and 64 cells). Compare to using other fluorescent pro-
teins such as GFP, an advantage of infrared is the low auto-
fluorescence signal from the growth medium and plastic,
thereby producing excellent signal-to-noise ratio. As infrared
imaging systems have a broad dynamic range, the signals
remained linear with at least 1000-fold difference in cell num-
ber (Figure 1D). Cell proliferation as measured by infrared was
comparable to conventionalmetabolic-basedmethods such as
WST-1 assays (Figure 1D), or more direct cell counting using
trypan blue staining and a haemocytometer (Figure 1E). Unlike
end-point assays such as WST-1 assays, the iRFP-expressing
cells remained viable after scanning. This allowed simple
and economical measurement of time-dependent changes in
cell number using the same plate (Figure 1F).
Collectively, we have developed a robust iRFP-based
screening platform, which is characterized by having a broad
linear range, high sensitivity, and can provide rapid and
economical time-dependent measurement of the effects of
drugs on cell growth. A similar infrared-based system and its
advantageshavealsobeendescribed recently (Hocketal., 2013).
3.2. Identification of compounds that act synergistically
with KIF11 inhibition
Using the iRFP-expressing cell platform, we next investigated
the cytotoxicity of the mitotic kinesin KIF11i SB743921 (Holen
et al., 2011). Incubation of iRFP-expressing HeLa cells with
SB743921 induced growth inhibition in a dose-dependent
manner (Figure 2A). Similar ED50 values were obtained from
infrared measurement and conventional WST-1 assays
(1.4 nM and 1.1 nM, respectively, at 96 h after drug addition),
further supporting the usefulness of the new infrared-based
proliferation assay (Figure 2B).
Flow cytometry analysis verified that 10 nM of SB743921
was sufficient to induced an accumulation of G2/M
(Figure S2A). Analysis of mitotic markers including cyclin B1
and phosphorylation of histone H3Ser10 and CDC27 confirmed
that SB743921 blocked cells in mitosis (Figure S2B). It is note-
worthy that the level of KIF11 was not altered in the presencethe relative cell proliferation after co-treatment with SB743921 was norma
relative proliferation after incubation with the compound alone (x-axis) or
predicted response if there was no change in cell proliferation between treatm
the predicted response for 75% reduction of cell proliferation in the combi
exerted strong effects on cytotoxicity when combined with SB743921 are in
with SB743921. The drugs and their reported targets are indicated. The re
SB743921 are shown. Isobologram analysis was performed (Materials and Mof SB743921. Finally, time-lapse microscopy (using cells
expressing histone H2B-GFP) confirmed that SB743921-
treated cells typically underwent protracted mitosis without
forming a metaphase plate before undergoing cell death
(Figure S2C).
To identify compounds that can potentiate the anti-
proliferation effects of SB743921, we treated iRFP-expressing
cells with a number of chemicals, either alone or in the pres-
ence of a relatively low concentration of SB743921 (1 nM). Dose
responses of the different compounds on HeLa cells were
tested beforehand to obtain sublethal concentrations
(Figure S1). The compounds were selected mainly based on
their potential cell cycle effects. Infrared imaging was used
to monitor which compounds, when combined with
SB743921, exerted strong anti-proliferation effects
(Figure 2C). Several compounds were found to have possible
synergistic effects with SB743921, causing more than 75%
reduction of cell proliferation in the combined treatment
compared to effect of the compounds individually (summa-
rized in Figure 2D). Not surprisingly, SB743921 itself was iden-
tified because the combinatorial treatment increased the
concentration of the drug. Other compounds that exerted
stronger effects than SB743921 included the Aurora kinase in-
hibitors Alisertib (also called MLN8237) and MK-5108 (also
called VX-689), and the PDK1 inhibitor BX795.
To investigate more rigorously if the effects of the above
chemicals and SB743921 together represented synergism, iso-
bologram analysis was carried out according to the median-
effectmethodofChouandTalalay (ChouandTalalay, 1984).Us-
ing infrared imaging to monitor proliferation, we found that
SB743921 acted synergistically with Alisertib, BX795, and MK-
5108 (Figure 2D). The combination index (CI) was less than 1,
which indicated synergism, over a range of effective dose
(ED50, ED75 and ED90; with the exception of Alisertib at ED90).
Taken together, these results indicate that the KIF11i
SB743921 induces mitotic arrest followed by cell death.
Furthermore, the anti-proliferation property of SB743921 is
enhanced by combination with several compounds that
include small-molecule inhibitors of Aurora kinases.
3.3. Aurora A inhibitors act synergistically with KIF11
inhibitors to induce mitotic catastrophe
Given the interests for both KIF11 and Aurora kinases as drug
targets, we performed detailed analysis of the interactions of
their inhibitors. On its own, SB743921 exerted negligible ef-
fects on proliferation at concentrations up to 1.25 nM after
48 h (Figure 3A). Likewise, Alisertib alone at concentrations
up to 31.3 nM did not affect proliferation. By contrast, prolifer-
ation was severely compromised in the presence of both
SB743921 and Alisertib. Similar results were obtained forlized to cells treated with SB743921 alone. Each dot represents the
in the presence of SB743921 ( y-axis). The solid line indicates the
ent alone and co-treatment with SB743921. The dashed line indicates
ned treatment compared to single drug treatment. Compounds that
dicated. (D) Summary of compounds that showed synergistic effects
lative proliferation of single drug treatment and in combination with
ethods). Combination index (CI) value< 1 indicates synergism.
Figure 3 e AURKAi acts synergistically with SB743921 to induce mitotic catastrophe. (A) Combinatorial treatment of Alisertib and SB743921
inhibits cell growth. HeLa cells were cultured in the presence of different concentrations of SB743921 and Alisertib for 48 h. Proliferation was
analyzed usingWST-1 assays. Mean ± SD of triplicates. (B) Long-term cell survival is inhibited by Alisertib and SB743921. HeLa cells were plated
at low density and cultured in the presence of the indicated concentrations of Alisertib and SB743921. After one week, the cells were fixed and
visualized with crystal violet staining. (C) Synergism between SB743921 and different AURKAi. HeLa cells were plated at low density and treated
with the indicated combination of Alisertib (62.5 nM), MK-5108 (125 nM), and SB743921 (1.25 nM). The colonies were fixed and stained with
crystal violet. The number of colonies was quantified. Mean ± SD of three independent experiments. (D) SB743921- and Alisertib-induced
monoastral spindle mitosis. HeLa cells were either untreated or exposed to SB743921 (1.25 nM) and Alisertib (62.5 nM) for 3 h. The proteasome
inhibitor MG132 was added for another 2 h to prevent mitotic exit. The cells were fixed, stained with antibodies against alpha-tubulin and gamma-
tubulin, and analyzed with fluorescent microscopy. Representative images are shown for mitosis with bipolar spindle and monoastral spindle. (E)
Targeting KIF11 and AURKA together induces monoastral spindle formation. Cells were treated with buffer, SB743921 (1.25 nM or 10 nM),
Alisertib (62.5 nM), and MK-5108 (125 nM) for 3 h. The proteasome inhibitor MG132 was added for another 2 h to prevent mitotic exit. The cells
were analyzed with fluorescence microscopy as in panel (D). The percentage of mitotic cells containing monoastral spindle is shown (n [ 80).
Mean ± SD of three independent experiments. (F) Targeting KIF11 and AURKA extends mitosis and promotes mitotic catastrophe. HeLa cells
expressing histone H2B-GFP were exposed to Alisertib (62.5 nM), MK-5108 (125 nM), and SB743921 (1.25 nM) as indicated. Individual cells
were tracked using time-lapse microscopy for 24 h. Each horizontal bar represents one cell (n[ 50). Key: grey[ interphase; black[mitosis (from
DNA condensation to anaphase or cell death); truncated bars [ cell death. (G) Normal mitotic exit is abolished by inhibition of KIF11 and
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survival after >2 weeks (Figure 3C). Survival was similarly
diminished after co-treatment with SB743921 and the Aurora
A (AURKA)-specific inhibitor MK-5108 (Figure 3C).
Although KIF11, AURKA, and Aurora B (AURKB) all regu-
late mitosis, distinct consequences are induced by their inhi-
bition. While KIF11i arrests cells in mitosis with monoastral
spindle, inhibitors of AURKA (AURKAi) and AURKB induce
mitotic arrest mainly with bipolar spindle and mitotic slip-
page, respectively (Marxer et al., 2013). We determine the
types of spindle defects in the combinatorial treatments
with immunofluorescence microscopy. Examples of bipolar
mitosis and monoastral mitosis are shown in Figure 3D. As
a control, 10 nM of SB743921 triggered monoastral spindle
formation in >90% of mitotic cells (Figure 3E). In contrast,
sublethal concentration of SB743921 (1.25 nM) did not elevate
the frequency of monoastral mitosis above the background.
Significantly, combining the sublethal concentration of
SB743921 with either Alisertib or MK-5108 restored monoas-
tral mitosis. As expected, the controls of Alisertib or MK-
5108 alone did not induce monoastral mitosis. These data
indicate that combining KIF11i with AURKAi produced an ef-
fect that is consistent with an inhibition of the KIF11
pathway.
We further used live-cell imaging to investigate the effects
of targeting KIF11 and AURKA together at single cells level.
The fates of individual cells stably expressing histone H2B-
GFP were tracked (Figure 3F). While incubation with sublethal
concentrations of KIF11i or AURKAi alone only increased the
mitotic duration marginally, combining KIF11i and AURKAi
dramatically increased the mitotic duration. Normal
anaphase was inhibited and the majority of cells eventually
succumbed to cell death during the prolonged mitotic block
(summarized in Figure 3G).
We further evaluated if the cell death triggered by co-
inhibition of KIF11 and AURKA involved apoptosis. As ex-
pected, the cell cycle profile was not significantly altered in
cells growing in sublethal concentrations of KIF11i or AURKAi
alone (Figure 4A). In contrast, combining KIF11i with either of
the two AURKAi promoted mitotic arrest as revealed by flow
cytometry (Figure 4A) and increase of histone H3Ser10 phos-
phorylation (Figure 4B). Apoptosis was suggested by an in-
crease in sub-G1 population (Figure 4A). As sub-G1
population is relatively less sensitive in detecting apoptosis,
we also used PARP1 cleavage (Figure 4B) as a further indictor
of apoptosis throughout this study.
It should be noted that at the concentrations used here, the
Aurora kinase inhibitors should only target AURKA. Using an-
tibodies against the activated forms of Aurora kinases and
other functional assays, we found that while MK-5108 exclu-
sively inhibits AURKA, Alisertib inhibits AURKA at relative
low concentrations and inhibits both AURKA and AURKB at
higher concentrations (Marxer et al., 2013). Unlike Alisertib,
the AURKB-specific inhibitor Barasertib did not act synergisti-
cally with KIF11i (Figure S3). An addition control including a
small-molecule inhibitor of CDK1 (RO3306) (Vassilev et al.,AURKA together. Cells were treated and analyzed with time-lapse microscop
normal anaphase (upper panel) or mitotic cell death (lower panel) is shown2006) further support the specificity of AURKAi in synergism
with KIF11i.
The synergistic actions between inhibitors of KIF11 and
AURKAwere not limited to one type of KIF11i. Another classic
KIF11i (monastrol) also acted in concerted with AURKAi to
promote mitotic catastrophe, as indicated by flow cytometry
(Figure 4C) and immunoblotting analysis (Figure 4D).
To further verify that the effective target of Alisertib and
MK-5108 in our assays was indeed AURKA, the inhibitors
were replaced with a siRNA specific for AURKA (siAURKA).
As we aimed to mimic the conditions in which sublethal con-
centrations of AURKAi were used, a relatively low concentra-
tion of siAURKAwas used in order to deplete AURKA partially.
Figure 4E shows that while neither siAURKA nor SB743921
affected the cell cycle, combination of the two treatments
inducedG2/M arrest and apoptosis. Protein analysis confirmed
the downregulation of AURKA as well as themitotic block and
apoptosis (Figure 4F). Conversely, we also used a siRNA to
partially deplete KIF11 (siKIF11) and demonstrated that
combining siKIF11 with AURKAi could promote G2/M arrest
and apoptosis (Figures 4G and 4H).
Collectively, these results indicate that AURKAi acts syner-
gistically with KIF11i to inducemonoastral spindle, mitotic ar-
rest, and eventually cell death.
3.4. KIF11-independent growth in SB743921-resistant
cell lines
Drug resistance is one of the major obstacles that impairs the
usefulness of many chemotherapeutic drugs. We generated
SB743921-resistant cells by exposing HeLa cells to progres-
sively increasing concentrations of SB743921 (Figure 5A), simi-
larly as previously described for another KIF11i called STLC
(Raaijmakers et al., 2012). After selection with 5 nM of
SB743921, some individual colonies were still sensitive to
10 nM of SB743921 (working concentration) similarly as the
parental HeLa cells. However, several cell lines (e.g. SBR1
and SBR4) were unaffected by 10 nM of SB743921 as indicated
by their cell cycle profiles (Figure 5B). Moreover, there was no
increase in histone H3Ser10 phosphorylation and PARP1 cleav-
age in SBR1 and SBR4 following SB743921 challenge
(Figure 5C). As expected, the SB743921-resistant cells were
able to formbipolar spindle (Figure 5D) and underwent normal
anaphase (Figure 5E) even in the presence of SB743921.
It is reasonable to surmise that the SB743921-resistant cell
lines could undergo KIF11-independent mitosis. To test this
hypothesis, we depleted KIF11 in these cells with siRNA
(siKIF11). In contrast to normal HeLa cells, which underwent
G2/M arrest and cell death, SB743921-resistant cell lines were
unaffected by siKIF11 (Figure 5F). Depletion of KIF11 in all
the cell lines was confirmed by immunoblotting (Figure 5G).
In agreement with the flow cytometry results, neither histone
H3Ser10 phosphorylation nor PARP1 cleavage was induced by
siKIF11 in the SB743921-resistant cell lines.
Collectively, these results indicate that SB743921-resistant
cell lines can undergo mitosis without KIF11.y as described in panel (F). The percentage of cells that could undergo
(n [ 50). Mean ± max/min of two independent experiments.
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Figure 4 e Mitotic catastrophe is induced by pharmacological or siRNA-mediated disruption of AURKA and KIF11. (A) Disruption of the cell
cycle by inhibitors of KIF11 and AURKA. HeLa cells were incubated with a combination of SB743921 (1.25 nM), Alisertib (62.5 nM), and MK-
5108 (125 nM). After 18 h, the cells were harvested and analyzed with flow cytometry. The percentage of sub-G1 cells is indicated. (B) Inhibition of
KIF11 and AURKA promotes mitotic catastrophe. Cells were treated as described in panel (A). Cell-free extracts were prepared and
phosphorylated histone H3Ser10 and cleaved PARP1 were detected with immunoblotting. Uniform loading of lysates was confirmed by
immunoblotting for actin. (C) Monastrol acts synergistically with AURKAi. HeLa cells were incubated with monastrol (25 mM) in the presence of
Alisertib (62.5 nM) or MK-5108 (125 nM). After 18 h, the cells were harvested and analyzed with flow cytometry. (D) Combination of monastrol
and AURKAi promote mitotic catastrophe. Cells were treated as described in panel (C). Cell-free extracts were prepared and analyzed with
immunoblotting. Actin analysis was included to assess protein loading and transfer. (E) Downregulation of AURKA sensitizes cells to SB743921.
HeLa cells were transfected with either control or a relatively low concentration of siRNA against AURKA (siAURKA) (22 pM). After 24 h, the
MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 4 0 4e1 4 1 81412
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 4 0 4e1 4 1 8 14133.5. Compensation of KIF11 in SB743921-resistant cells
by KIF15
What is molecular basis of KIF11-independent growth? The
expression of KIF11 itself probably was not a major factor as
it was either unchanged or marginally decreased in some
SB743921-resistant clones (Figures 5G and 6A). One possibility
is that KIF11 functions may be compensated by the kinesin
KIF15 as previously reported (Tanenbaum et al., 2009). We
found that KIF15 was indeed overexpressed in a subset of
the SB743921-resistant cell lines (e.g. SBR4) (Figure 6A).
Consistent with this finding, the mRNA of KIF15 in SBR4 was
increased in comparison to HeLa cells (Figure 6B). But KIF15
overexpression did not occur in all SB743921-resistant cell
lines (e.g. SBR1).
To test directly if KIF15 was involved in compensating for
the activity of KIF11 in SB743921-resistant cells, KIF15 was
depleted before SB743921 was added. While control SBR1
and SBR4 were resistant to SB743921-mediated G2/M arrest,
they became sensitized to the drug after KIF15 was downregu-
lated (Figure 6C). This was also reflected by the increase in his-
tone H3Ser10 phosphorylation and PARP1 cleavage (Figure 6D).
Neither the cell cycle progression (Figure 6C) nor cell death
(Figure 6D) was affected by siKIF15 alone.
These data indicate that while a subset of SB743921-
resistant cell lines were characterized by an increase
in KIF15, others contained similar levels of KIF15 as
control cells. Nevertheless, depletion of KIF15 could sensi-
tize these SB743921-resistant cell lines to mitotic catastro-
phe, suggesting that KIF11 functions were in part taken
over by KIF15.
3.6. KIF11 drug-resistance can be overcome by targeting
AURKA
Given that no specific inhibitor of KIF15 has been developed
yet, we next tested if AURKAi could promotemitotic cell death
in SB743921-resistant cells (Figure 7A). As shown above, SBR1
and SBR4 did not respond to 10 nM of SB743921. Notably,
SB743921 alone was incapable to induce mitotic catastrophe
in SB743921-resistant cells even when used at 100 nM
(Figure 7B). Co-treatment with AURKAi, however, induced
mitotic arrest in these cell lines (Figure 7A). Mitotic arrest
and cell death were confirmed by histone H3Ser10 phosphory-
lation and PARP1 cleavage, respectively (Figure 7B). In agree-
ment with the inhibition of KIF11 pathway, targeting AURKA
promoted monoastral formation in SB743921-resistant cells
(Figure 7C). As expected, the long-term cell survival of
SB743921-resistant cells treated with SB743921 was also
reduced upon co-incubation with AURKAi (Figure 7D).cells were treated with either buffer or SB743921 (1.25 nM). After 18 h, th
Downregulation of AURKA sensitizes cells to SB743921. Cells were transf
prepared and analyzed with immunoblotting. Depletion of AURKA and un
AURKA and actin respectively. (G) Downregulation of KIF11 sensitizes c
relatively low concentration of siRNA against KIF11 (siKIF11) (66 pM). Aft
5108 (125 nM). After 18 h, the cells were harvested and analyzed with flow
Cells were transfected and treated as described in panel (G). Cell-free extr
KIF11 and uniform loading of lysates were confirmed by immunoblottingTo ensure that the ability of AURKAi to overcome
SB743921-resistance was not limited to HeLa cells, we also
used a similar strategy to generate SB743921-resistant cell
lines based on the lung carcinoma H1299 cells. In contrast to
the parental cells, the SB743921-resistant H1299 cells were
insensitive to 10 nM of SB743921 (Figure S4A). Treatment of
these cells with AURKAi sensitized them to SB743921
(Figure S4B), indicating that co-inhibition of KIF11 and AURKA
could overcome KIF11i-resistant cell lines from different
origins.
Taken together, these results indicate that targeting
AURKA and KIF11 together can overcome drug-resistance
developed against KIF11i.4. Discussion
KIF11 has been the focus of several drug candidates in devel-
opment. However, results from clinical trials of the best-
characterized compound, Ispinesib (SB715992), have been un-
impressive (Rath and Kozielski, 2012). Encouraging results
have been obtained with the second-generation Ispinesib
analog SB743921, with partial response in a cholangiocarci-
noma patient and stable disease in patients with relapsed
lymphoma or advanced solid tumors (Holen et al., 2011). Rea-
sons that KIF11i in general are only marginally successful in
clinical studies may include the lack of potency and develop-
ment of drug-resistance. Both of these problems can in princi-
ple be tackled by combinatorial treatment with another
antimitotic drug. Tests of combinatorial treatment with
KIF11i have so far been limited to traditional genotoxic agents
(Rath and Kozielski, 2012). Here we discovered that the effi-
cacy of KIF11i could be markedly increased by combination
with AURKAi (Alisertib and MK-5108). Both Alisertib and MK-
5108 are themselves drug candidates undergoing Phase I and
II clinical trials (Marzo and Naval, 2013).
Synergism between SB743921 and AURKAi was demon-
strated using a number of approaches, including infrared-
(Figure 2D) and WST-1-based (Figure 3A) cell proliferation as-
says, isobologram analysis (Figure 2D), clonogenic survival as-
says (Figures 3B and 3C), monoastral spindle formation
(Figures 3D and 3E), live-cell imaging (Figures 3F and 3G),
flow cytometry (Figure 4A), and protein analysis (Figure 4B).
The specificity of the combinatorial treatment for KIF11 was
verified with two different KIF11i (Figures 4C and 4D) and a
siRNA against KIF11 (Figures 4G and 4H). Likewise, the speci-
ficity for AURKA was validated with two different AURKAi
(Figures 3 and 4) and siRNA against AURKA (Figures 4E and
4F). It was further supported by the fact that an AURKB-e cells were harvested and analyzed with flow cytometry. (F)
ected and treated as described in panel (E). Cell-free extracts were
iform loading of lysates were confirmed by immunoblotting for
ells to AURKAi. HeLa cells were transfected with either control or a
er 24 h, the cells were treated with buffer, Alisertib (62.5 nM), or MK-
cytometry. (H) Downregulation of KIF11 sensitizes cells to AURKAi.
acts were prepared and analyzed with immunoblotting. Depletion of
for KIF11 and actin respectively.
Figure 5 e KIF11-independent growth in SB743921-resistant cell lines. (A) Isolation of SB743921-resistant cell lines. HeLa cells were treated with
a schedule of increasing concentrations of SB743921 as depicted. Individual colonies that could grow in 5 nM of SB743921 were isolated and
designated as SBR1-6. (B) SB743921-resistant cells are insensitive to SB743921-mediated mitotic arrest. The parental HeLa cells and different
SB743921-resistant cell lines were treated with 10 nM of SB743921 for 18 h. The cells were then harvested for cell cycle analysis with flow
cytometry. (C) SB743921-resistant cells are insensitive to SB743921-mediated mitotic catastrophe. The parental HeLa cells and different
SB743921-resistant cell lines were treated with 10 nM of SB743921 for 18 h. Cell-free extracts were prepared and the indicated proteins were
detected by immunoblotting. (D) SB743921-resistant cells do not form monoastral spindle upon SB743921 challenge. HeLa, SBR1, and SBR4
cells were treated with SB743921 (10 nM) for 3 h. MG132 was added for another 2 h to trap cells in mitosis. The cells were then fixed and stained
with antibodies against g-tubulin and a-tubulin. The percentage of mitotic cells containing monoastral spindle was quantified using fluorescence
microscopy (n[ 80). Mean ± SD of three independent experiments. (E) SB743921-resistant cells can undergo normal anaphase in the presence of
SB743921. HeLa and SBR1 cells were transfected with a plasmid expressing histone H2B-GFP. The cells were either untreated or incubated in
with SB743921 (10 nM) as indicated, and analyzed using live-cell imaging. Representative time-lapse images of mitotic cells are shown. (F)
SB743921-resistant cells can undergo KIF11-indepenent cell cycle progression. HeLa, SBR1, and SBR4 cells were transfected with control or
siKIF11. After 48 h, the cells were harvested and analyzed with flow cytometry. (G) Depletion of KIF11 in SB743921-resistant cells does not
induce mitotic catastrophe. HeLa, SBR1, and SBR4 cells were transfected with control or siKIF11. After 48 h, the cells were harvested and
analyzed with immunoblotting.
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Figure 6 e Compensation of KIF11 activity by KIF15. (A) Increase of KIF15 in a subset of SB743921-resistant cell lines. Protein expression inHeLa,
SBR1, and SBR4 cells was detectedwith immunoblotting. Actin analysis was included to assess protein loading and transfer. (B)ThemRNAofKIF15
is elevated in a subset of SB743921-resistant cell lines. The levels of mRNA ofKIF15 and TPX2 in HeLa, SBR1, and SBR4 cells were measured with
RT-PCR.Mean ± SD of six samples (two sets of triplicates). (C)Downregulation of KIF15 overcomes SB743921-resistance. HeLa, SBR1, and SBR4
cells were transfected with either control or siKIF15. After 24 h, the cells were incubatedwith either buffer or SB743921 (10 nM) for another 24 h. The
cells were then harvested and analyzed with flow cytometry. (D) Downregulation of KIF15 overcomes SB743921-resistance. HeLa, SBR1, and SBR4
cells were transfected and treated as described in panel (C). Cell-free extracts were prepared and analyzed with immunoblotting.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 4 0 4e1 4 1 8 1415specific inhibitor (Barasertib) did not cooperate with KIF11 in-
hibition (Figure S3).
These results are consistent with some available data on
KIF11i and AURKA. In a study using a KIF11i called KSP-1A,
Jackson et al. found that genes predicting resistance to the
KIF11i are enriched on chromosome 20q, a region frequently
amplified in tumors (Jackson et al., 2008). Moreover, siRNAs
targeting genes in this chromosomal region revealed that
disruption of AURKA, TPX2, and MYBL2 enhances response
to KIF11i.
What is the mechanistic basis of the link between KIF11
and AURKA? One possibility is that AURKA acts directly on
KIF11 (Figure 7E, Model I). Although in Xenopus, the AURKA-
related protein Eg2 associates with and phosphorylates
KIF11 (Giet et al., 1999), direct evidence of interaction between
human KIF11 and AURKA has yet to be demonstrated. Never-
theless, KIF11 is phosphorylated by other mitotic kinases
including CDK1 (Blangy et al., 1995), NEK6 (Rapley et al.,
2008), and NEK9 (Bertran et al., 2011). Hence the regulation
of KIF11 by AURKA (if any) is unlikely to be exclusive. Unlike
the inhibition of KIF11, which induced monoastral spindle,
complete inhibition of AURKAmainly resulted inmitotic block
with bipolar spindle, with w25% of cells showing monopolar
andmultipolar spindle (Figure S5). This indicates that a simplelinear mechanism such as Model I is not sufficient to explain
the data.
AURKA itself localizes to centrosomes (Gopalan et al.,
1997); and several lines of evidence indicate that AURKA is
an important regulator of centrosome function. For example,
AURKA is required for centrosomematuration and separation
in Drosophila (Berdnik and Knoblich, 2002; Glover et al., 1995).
Several proteins, including TACC, LATS2, cyclin BeCDK1,
and CDC25B are targeted to the centrosome by AURKA
(Fukasawa, 2007). It is possible that due to the distinct func-
tions of AURKA and KIF11 on the centrosome, targeting both
proteins together resulted inmore extensive defects in centro-
some maturation and separation (Figure 7E, Model II).
Remarkably, concurrent inhibition of AURKA and KIF11
also sensitized SB743921-resistant cells to mitotic catastro-
phe. A number of underlying mechanisms could be envisaged
to account for KIF11i-resistance. Overexpression of multidrug
transporters including P-glycoprotein is a common mecha-
nism of multidrug-resistance. Mutations of KIF11 could also
render it less sensitive to KIF11i. In this connection, it was re-
ported that Ispinesib-resistant HCT116 cells contain two point
mutations in the KIF11 allosteric binding pocket, D130V and
A133D, generating inhibitor-resistant but otherwise catalyti-
cally competent KIF11 (Knight and Parrish, 2008).
AB C
D E
Figure 7 e Inhibition of AURKA overcomes KIF11 drug-resistance. (A) AURKAi and SB743921 act synergistically on SB743921-resistant cells.
HeLa, SBR1, and SBR4 were treated with SB743921 in the presence of either Alisertib (62.5 nM) or MK-5108 (125 nM) for 18 h before analyzed
with flow cytometry. (B) AURKAi and SB743921 overcome SB743921-resistance. SBR1 cells were treated with SB743921 in the presence or
absence of Alisertib (62.5 nM) for 24 h. Cell-free extracts were prepared and analyzed with immunoblotting. Note that even at a very high
concentration, SB743921 (100 nM) alone did not overcome SB743921-resistance. (C) Targeting AURKA promotes monoastral spindle formation
in SB743921-resistant cells. HeLa, SBR1, and SBR4 were treated with SB743921 (10 nM), Alisertib (62.5 nM), and MK-5108 (125 nM) for 3 h.
The proteasome inhibitor MG132 was added for another 2 h to prevent mitotic exit. The cells were fixed, stained with antibodies against a-tubulin
and g-tubulin, and analyzed with fluorescence microscopy. The percentage of mitotic cells containing monoastral spindle is shown (n [ 80).
Mean ± SD of three independent experiments. (D) Long-term cell survival of SB743921-resistant cells is reduced by targeting KIF11 and AURKA.
HeLa, SBR1, and SBR4 were plated at low density and cultured in the presence of SB743921 (10 nM), Alisertib (62.5 nM), and MK-5108
(125 nM). After one week, the cells were fixed and visualized with crystal violet staining. (E) Models of the relationship between AURKA, KIF11,
and KIF15 in the regulation of centrosomal functions. In KIF11i-sensitive cells, AURKA could act upstream of KIF11 (Model I) or in parallel
pathways (Model II) in regulating centrosome maturation and separation. In KIF11i-resistant cells, some of KIF11’s functions are compensated by
KIF15. AURKA could act upstream of KIF11 and KIF15 (Model III). Alternatively, AURKA could act on the centrosome independently (Model
IV). The models are not necessary mutually exclusive.
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steric effects at the binding site, but through reduction of flex-
ibility and allosteric transmissions after inhibitor binding
(Talapatra et al., 2013). Finally, another process specific for
antimitotic drug-resistance is mitotic slippage, by which cells
exit mitosis prematurely without sister chromatid separation.
We believe that the above processes (transporter, KIF11
mutation, and mitotic slippage) were unlikely to be explana-
tions for KIF11i-resistance described here. It is because the
SB743921-resistant cells were insensitive to siRNA-mediated
depletion of KIF11 (Figures 5F and 5G), indicating that they
could grow independently of KIF11. Furthermore, KIF11 was
still important if KIF15 function was compromised (Figures
6C and 6D). Under these conditions, KIF11 was still sensitive
to 10 nM of SB743921 (arguing against the involvement of
multidrug transporters and KIF11 mutations) and underwent
mitotic arrest (arguing against mitotic slippage).
Several mechanisms that act in parallel to KIF11 in regu-
lating centrosome separation have been described. For
example, dynein-dependent mechanisms may counteract
KIF11 in microtubule sliding (Tanenbaum et al., 2008),
although there is evidence that dynein may antagonize
KIF11 indirectly rather than through a simple pushepull
mechanism at the spindle equator (Florian and Mayer, 2012).
Other mechanisms that act parallel with KIF11 include EGFR
signaling (Mardin et al., 2013), a nuclear envelope-associated
dynein pathway (Raaijmakers et al., 2012), and KIF15
(Tanenbaum et al., 2009). SB743921-resistance appeared to
be due to compensation of KIF11 functions by KIF15. Intrigu-
ingly, not all SB743921-resistant clones contained overex-
pressed KIF15 mRNA and protein (Figures 6A and 6B). Both
types of SB743921-resistant cells became sensitive to
SB743921 after KIF15 was depleted (Figures 6C and 6D). How
the unchanged level of KIF15 substituted for KIF11 functions
remained to be deciphered. Our data are consistent with a
model that in the SB743921-resistant cells, the usual functions
of KIF11 was partially taken over by KIF15. The reasoning is
based on the fact that while KIF11i or siKIF15 separately was
unable to promote mitotic catastrophe, inhibition of both
KIF11 and KIF15 together induced mitotic catastrophe.
Our findings also support that SB743921 does not target
KIF15; otherwise SB743921 should be able to trigger a mitotic
arrest in SB743921-resistant cells. The cells were insensitive
even when challenged with 100 nM of SB743921, 10x the con-
centration normally required to induce mitotic arrest
(Figure 7B).
As no specific inhibitor of KIF15 has been developed yet,
our data indicate that targeting AURKA is an effective option
to overcome KIF11i-resistance (Figure 7). Co-treatment of
SB743921-resistant cells with AURKAi and SB743921 promoted
monoastral spindle formation, mitotic arrest, and cell death.
As in KIF11i-sensitive cells, AURKA could either act upstream
of KIF11 (and KIF15) or in an independent pathway (Figure 7E,
Models III and IV). Given the effects of AURKAi alone on
centrosome (Figure S5), Model IV is perhaps more favorable.
In conclusion, pharmacological inhibition of AURKA can
enhance mitotic catastrophe induced by KIF11i, most likely
because both AURKA and KIF11 regulate centrosome func-
tions independently. Moreover, targeting AURKA can also
overcome KIF15-dependent KIF11i-resistance.Conflict of interest
There is no conflict of interest.
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